Literature DB >> 20630441

Strategies to optimize pain management with opioids while minimizing risk of abuse.

Michael J Brennan1, Steven Stanos.   

Abstract

More than 75 million Americans have chronic or recurring pain [1]. Such pain negatively impacts emotional and mental health, quality of life, and productivity and increases the use of health care resources [1-5]. Prescription opioids are widely used and may be effective analgesics for chronic, moderate-to-severe pain in appropriately selected patients, particularly when used as part of comprehensive pain management plans [4,6]. The increased use of prescription opioids over the last decade has been mirrored in an increase in the reported misuse, abuse, and diversion of these agents. Physician reluctance to initiate opioid therapy may lead to undertreatment of pain [7,8]. Clinicians can implement procedures such as careful patient screening and ongoing monitoring to ensure that risk of opioid abuse is minimized without interfering with the appropriate use for patients with legitimate chronic noncancer pain. Efforts are being made nationally, statewide, and locally to inform and educate medical professionals, policymakers, the public health community, and patients concerning the benefits and risks of opioid therapy for chronic pain. Monitoring programs are currently being adopted to document and discourage misuse, abuse, and diversion of prescription opioids. The US Food and Drug Administration recently initiated hearings to examine a potential change in the government's risk management plan, Risk Evaluation and Mitigation Strategies [9], which could dramatically change the development, release, marketing, and prescription of extended-release opioids. Pharmaceutical companies have remained active in developing products that are potentially less attractive for abuse. The challenge of balancing the availability of prescription opioids to treat patients who have pain while discouraging illicit use is complex, requiring effective efforts on many levels. Copyright 2010 American Academy of Physical Medicine and Rehabilitation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20630441     DOI: 10.1016/j.pmrj.2010.03.011

Source DB:  PubMed          Journal:  PM R        ISSN: 1934-1482            Impact factor:   2.298


  9 in total

1.  Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects.

Authors:  Mona Darwish; Mary Bond; William Tracewell; Philmore Robertson; Ronghua Yang
Journal:  Clin Drug Investig       Date:  2015-01       Impact factor: 2.859

Review 2.  Drug Formulation Advances in Extended-Release Medications for Pain Control.

Authors:  Mark R Jones; Martin J Carney; Rachel J Kaye; Amit Prabhakar; Alan D Kaye
Journal:  Curr Pain Headache Rep       Date:  2016-06

3.  Leading causes of unintentional and intentional injury mortality: United States, 2000-2009.

Authors:  Ian R H Rockett; Michael D Regier; Nestor D Kapusta; Jeffrey H Coben; Ted R Miller; Randy L Hanzlick; Knox H Todd; Richard W Sattin; Leslie W Kennedy; John Kleinig; Gordon S Smith
Journal:  Am J Public Health       Date:  2012-09-20       Impact factor: 9.308

Review 4.  Measurement of Chronic Pain and Opioid Use Evaluation in Community-Based Persons with Serious Illnesses.

Authors:  Kathleen Puntillo; Ramana K Naidu
Journal:  J Palliat Med       Date:  2017-11-01       Impact factor: 2.947

Review 5.  Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering.

Authors:  Steven P Stanos; Patricia Bruckenthal; Robert L Barkin
Journal:  Mayo Clin Proc       Date:  2012-07       Impact factor: 7.616

6.  Experience with an extended-release opioid formulation designed to reduce abuse liability in a community-based pain management clinic.

Authors:  Daniel Rubino
Journal:  Int J Gen Med       Date:  2011-09-19

7.  A long-term, open-label safety study of single-entity hydrocodone bitartrate extended release for the treatment of moderate to severe chronic pain.

Authors:  Srinivas Nalamachu; Richard L Rauck; Martin E Hale; Orlando G Florete; Cynthia Y Robinson; Stephen J Farr
Journal:  J Pain Res       Date:  2014-11-21       Impact factor: 3.133

8.  "Pill Pushers and CBD Oil"-A Thematic Analysis of Social Media Interactions About Pain After Traumatic Brachial Plexus Injury.

Authors:  Emma T Smolev; Liz Rolf; Eric Zhu; Sarah K Buday; Madison Brody; David M Brogan; Christopher J Dy
Journal:  J Hand Surg Glob Online       Date:  2020-11-13

9.  Is intravenously administered, subdissociative-dose KETAmine non-inferior to MORPHine for prehospital analgesia (the KETAMORPH study): study protocol for a randomized controlled trial.

Authors:  Clément Le Cornec; Said Lariby; Vivien Brenckmann; Jean Benoit Hardouin; Claude Ecoffey; Marion Le Pottier; Philippe Fradin; Hélène Broch; Amine Kabbaj; Yannick Auffret; Florence Deciron; Céline Longo; François Javaudin; Quentin Le Bastard; Joël Jenvrin; Emmanuel Montassier
Journal:  Trials       Date:  2018-05-02       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.